Michael is a co-founder and CEO of Presidio Medical. Michael also serves as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST) and Chairman of Tarsus Pharmaceuticals, Inc. He was previously Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan. He received a B.E. degree in biomedical engineering from Vanderbilt University, M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University, is a graduate of the Stanford University Biodesign Fellowship and Vision Research Fellowship at Stanford University. He has numerous patents and peer-reviewed publications.
PhD, President & CTO
Kenneth is a co-founder and President & CTO of Presidio Medical. He was previously COO of Siris Medical, Inc an AI platform for enhancing radiation oncology treatment planning and outcomes. Prior to that, he was an R&D Program Manager at Spiracur Inc., a company focused on wound healing therapies, moving multiple products through early development to commercial release including FDA clearance and manufacturing implementation. Spiracur’s technology was acquired by Acelity L.P. He received his B.S.E. degree in mechanical and aerospace engineering from Princeton University, M.S. and Ph.D. degrees in mechanical engineering from Stanford University and is a graduate of the Stanford University Biodesign Fellowship.
MD, Chief Medical Officer
Andrew is Chief Medical Officer of Presidio Medical. Prior to Presidio, Andrew was in full-time practice as a board-certified anesthesiologist with Boulder Valley Anesthesiology as a full partner and member of the Executive Committee. During medical practice, Andrew was engaged in industry as an active consultant. He finished degrees in Biology and History, as well as his Medical Doctorate, from Indiana University. He completed his residency in Anesthesiology at the University of Colorado.
Vice President, Implantable Systems
Mike is Vice President of Implantable Systems at Presidio Medical. He was previously CTO at the bioelectronic medicine company SetPoint Medical where he helped transform the idea of modulating the Cholinergic Inflammatory pathway into a ground-breaking Class III medical product. Starting in 1994, he architected and developed cochlear implants for Advanced Bionics from the startup stage through the acquisition by Boston Scientific. He served as the System Architect and then Vice President of R&D. At Advanced Bionics he worked with the engineers at Scond Sight, Advanced Bionics SCS, DBS, and BION programs. Mike recieved his B.S.E. from University of California, Irvine.